Sanara MedTech (SMTI) Projected to Post Quarterly Earnings on Wednesday

Sanara MedTech (NASDAQ:SMTI) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.33) per share and revenue of $25.15 million for the quarter.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). The company had revenue of $23.43 million for the quarter, compared to analyst estimates of $23.48 million. Sanara MedTech had a negative return on equity of 29.22% and a negative net margin of 12.48%. On average, analysts expect Sanara MedTech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sanara MedTech Stock Performance

NASDAQ:SMTI opened at $26.86 on Tuesday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.54 and a current ratio of 2.77. The company has a fifty day moving average of $27.62 and a two-hundred day moving average of $30.60. The stock has a market capitalization of $238.79 million, a PE ratio of -20.04 and a beta of 1.26. Sanara MedTech has a fifty-two week low of $23.53 and a fifty-two week high of $39.08.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price objective on shares of Sanara MedTech from $51.00 to $53.00 and gave the stock a “buy” rating in a research report on Thursday, May 15th.

Hedge Funds Weigh In On Sanara MedTech

A hedge fund recently raised its stake in Sanara MedTech stock. Rhumbline Advisers boosted its stake in shares of Sanara MedTech Inc. (NASDAQ:SMTI) by 14.9% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 3,714 shares of the company’s stock after acquiring an additional 483 shares during the period. Rhumbline Advisers’ holdings in Sanara MedTech were worth $115,000 at the end of the most recent quarter. 8.10% of the stock is owned by hedge funds and other institutional investors.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.